Phase 2 Trial Results Presented of Corbus’ Anabasum as Treatment for Systemic Sclerosis

Author: Joana Fernandes, PhD
Date Published: June-2017
Source: Scleroderma News

Results of a Phase 2 clinical trial (NCT02465437) evaluating the effects of Corbus Pharmaceuticals’ anabasum (formerly known as Resunab or JBT-101) support this treatment as a potential option for patients with diffuse cutaneous systemic sclerosis. The study showed that treatment with anabasum affects the activity of nearly 1,940 genes associated with different mechanisms, including molecules associated with inflammation, skin regulation and structure, and fat metabolism.